A recent systematic review and meta-analysis published in JAMA Psychiatry has investigated the association between glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and suicidal risk in adults with diabetes or obesity. The study analyzed data from 144 randomized clinical trials, comparing GLP-1 RAs to placebo.
The researchers found that the incidence of completed or attempted suicide was very low for both groups, with no statistically significant difference observed between GLP-1 RA treatment and placebo. The findings also showed no variation in outcome based on diabetes status or the specific GLP-1 RA used.
While the study’s results ease concerns about suicidal adverse effects associated with GLP-1 RAs, the researchers emphasized that continued monitoring is necessary to identify patients who may be at risk as extended use of these medications expands. The low incidence of suicide-related events in clinical trials suggests that GLP-1 RAs are unlikely to increase the risk of suicidal behavior in this population.
Source: https://www.docwirenews.com/post/systematic-review-of-suicide-self-harm-potentiality-in-glp-1-ra-trials